NCT00085696CompletedPhase 2
A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Millennium Pharmaceuticals, Inc.13 sites in 1 country66 target enrollmentStarted: May 1, 2004Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 66
- Locations
- 13
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female subject 18 years or older
- •Diagnosis of B-cell lymphoma (CD20+) of
- •follicular lymphoma (grades 1, 2, and 3) or
- •marginal zone lymphoma (extranodal, nodal, and splenic)
- •Documented relapse or progression following prior anti-neoplastic treatment.
- •At least 1 measurable lymph node mass that is >1.5 cm.
- •No active CNS lymphoma
- •Voluntary consent
Exclusion Criteria
- •Previous treatment with VELCADE
- •Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug.
- •Any treatment with nitrosoureas within 6 weeks before the first dose of study drug.
- •Treatment with Zevalin™ or Bexxar® within 10 weeks before the first dose of study drug.
- •Rituximab, Campath® or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug.
- •Radiation therapy within 3 weeks before the first dose of study drug.
- •Major surgery within 2 weeks before the first dose of study drug.
- •Peripheral neuropathy or neuropathic pain
- •History of allergic reaction attributable to compounds containing boron or mannitol
- •Known anaphylaxis or hypersensitivity to any component of rituximab
- •Diagnosed or treated for a selected malignancies other than NHL within 5 years.
- •Active systemic infection requiring treatment
- •Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study.
- •Male subjects who do not agree to use an acceptable method of contraception for the duration of the study
- •Any serious medical or psychiatric illness likely to interfere with participation in this clinical study
- •Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
Investigators
Study Sites (13)
Loading locations...
Similar Trials
Completed
Phase 2
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaFollicular LymphomaNCT00636792Millennium Pharmaceuticals, Inc.73
Completed
Phase 2
VELCADE® Plus Rituximab in Non Hodgkin's Follicular LymphomaNon Hodgkin's Follicular LymphomaNCT01830465Gruppo Italiano Studio Linfomi45
Completed
Phase 2
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaMantle Cell LymphomaNCT00201877Ohio State University Comprehensive Cancer Center25
Completed
Phase 1
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaMantle Cell LymphomaNCT00477412M.D. Anderson Cancer Center107
Completed
Phase 2
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT00531453Millennium Pharmaceuticals, Inc.98